In 110 postmenopausal women with moderate-to-severe vasomotor symptoms and sleep disturbance, elinzanetant 120 mg vs placebo was estimated to cut polysomnographic WASO at week 4 (−22.5 min) but not at week 12 (−0.94 min); post hoc modelling favoured elinzanetant.
Secondary analysisn = 110
Baker et al. Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study